Biomarkers of Insulin Resistance and Their Performance as Predictors of Treatment Response in Overweight Adults
Authors' conclusion
We demonstrate that the choice of insulin assay is critical when quantifying the influence of treatment on fasting insulin, whereas none of the clinical-metabolomic biomarkers, identified in cross-sectional studies, are suitable for monitoring longitudinally changes in IR status.
Study context
- Population
- Overweight adults receiving lifestyle-based interventions3 cohorts
- Participants
- 179 / 116 / 149
- Comparison
- Clinical-metabolomic biomarker models and two insulin assays (high-sensitivity ELISA vs immunoassay) for insulin resistance (IR) and treatment response
- META-PREDICTn = 179
- STRRIDE-AT/RTn = 116
- STRRIDE-PDn = 149
- Outcome
- Performance of clinical and metabolomic biomarker models to forecast altered IR following lifestyle-based interventions
Methodological details3 independent cohorts, lifestyle-based interventions, linear and Bayesian projective prediction
- 3 independent cohorts
- Lifestyle-based interventions
- Linear and Bayesian projective prediction
Main finding
As reported in the abstract
Biomarker model performance
Clinical-metabolomic models statistically related to fasting insulin (R2)
0.33-0.39
Further findings
Insulin assay performance
- Both assays accurately quantified international standard insulin (R2)
- > 0.99
- Agreement between fasting insulins (R2)
- 0.65
- Mean treatment effect on fasting insulin only detectable using the ELISA
Original publication
Biomarkers of Insulin Resistance and Their Performance as Predictors of Treatment Response in Overweight Adults. J Clin Endocrinol Metab. Published 13 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →